Abstract
Biologic drugs, including monoclonal antibodies, vaccines, and recombinant proteins, have revolutionized the treatment of various diseases such as cancer, autoimmune disorders, and infectious diseases. This article explores recent advances in biologic drug production and formulation technologies, focusing on innovations in biomanufacturing processes, formulation strategies, and delivery systems. It highlights the integration of cell culture-based production platforms, improvements in drug stability and bioavailability, and the role of novel excipients in enhancing therapeutic outcomes. Future trends, including personalized biologics and bioprinting, are also discussed. The ongoing advancements in biologic drug development promise to improve therapeutic efficacy and accessibility for patients worldwide.
All articles published in the American Journal of Pharmaceutics are open access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given, a link to the license must be provided, and any changes must be indicated.
-
Authors retain full copyright of their work.
-
The journal does not restrict reuse of content, provided proper citation of the original publication is made.